The Centers for Medicare & Medicaid Services (CMS) issued a ground-breaking draft national coverage decision (NCD) on January 11, 2022, for Food & Drug Administration (FDA) approved monoclonal ...
Medicare is poised to revise its “coverage with evidence development” (CED) policy, which has important implications for beneficiaries’ access to new medical technology as well as manufacturers’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback